CheckMate 77TPerioperative Nivolumab in Resectable Lung Cancer Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the CheckMate 77T trial, comparing the outcomes of perioperative nivolumab combined with … Read More
lung cancer
![](https://www.visualmed.org/wp-content/uploads/2024/04/NADIM-II.jpg)
NADIM II Trial: Nivolumab in Lung Cancer
Objective: To examine the pathological Complete Response defined as the absence of residual tumor in lung and lymph nodes comparing patients treated with chemo-immunotherapy versus chemotherapy alone. Inclusion Criteria: Exclusion Criteria: Participants: 86 Patients Treatment Groups: Primary Outcome: Secondary Outcomes: … Read More
![](https://www.visualmed.org/wp-content/uploads/2024/04/LIBRETTO-431.jpg)
LIBRETTO-431 Trial: Selpercatinib in NSCLC
Objective: To determine if the study drug selpercatinib, compared to a standard treatment, is effective and safe in participants with RET fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Inclusion Criteria: Participants: … Read More
![](https://www.visualmed.org/wp-content/uploads/2023/10/AEGEAN.jpg)
NSCLC Treatment: The AEGEAN Trial Breakthrough
“Innovations in NSCLC Treatment: The AEGEAN Trial Breakthrough” In recent years, the pursuit of more effective treatments for non-small-cell lung cancer (NSCLC) has been relentless. The AEGEAN trial of 2023, as reported in the esteemed New England Journal of Medicine … Read More
![](https://www.visualmed.org/wp-content/uploads/2023/06/KEYNOTE-671.jpg)
KEYNOTE 671 Trial: Perioperative Pembrolizumab in Early-Stage NSCLC
KEYNOTE 671 Trial Summary Introduction:The KEYNOTE 671 trial aimed to investigate the efficacy of perioperative pembrolizumab, an immune checkpoint inhibitor, in patients with resectable early-stage non–small-cell lung cancer (NSCLC). This randomized, double-blind, phase 3 trial assessed the benefits of neoadjuvant … Read More